Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
VBI Vaccines Inc/BC reported financial results for the first fiscal quarter ending March 31, 2024.
- Period
- the first fiscal quarter ending March 31, 2024
- Result
- reported results
Exact text from the filing
On May 15, 2024, the Company issued a press release announcing its financial results for the first fiscal quarter ending March 31, 2024, and provided a corporate update. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.97
VBI Vaccines Inc/BC terminated Open Market Sale Agreement with Jefferies LLC valued at Terminated prior ATM offering of up to $125,000,000 (effective 2024-05-10).
- Action
- termination
- Agreement
- equity purchase
- Counterparty
- Jefferies LLC
- Value
- Terminated prior ATM offering of up to $125,000,000
- Effective
- 2024-05-10
Exact text from the filing
Effective as of May 10, 2024, the Company terminated (i) the Jefferies Sales Agreement, pursuant to Section 7(b)(i) of the Jefferies Sales Agreement, and (ii) the Prior ATM Offering.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.98
VBI Vaccines Inc/BC entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $8,468,289 (effective 2024-05-15).
- Action
- entry
- Agreement
- atm program
- Counterparty
- H.C. Wainwright & Co., LLC
- Value
- up to $8,468,289
- Effective
- 2024-05-15
Exact text from the filing
On May 15, 2024, VBI Vaccines Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time through Wainwright, common shares, no par value per share (the “Shares”), for aggregate gross proceeds of up to $8,468,289 (the “ATM Offering”).
View on SEC.gov